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Hematopoietic stem cell transplantation (HCT) is a potentially life-saving therapy for patients with malignant
and nonmalignant disease states. This article reviews the current published literature on the dosing of
pharmacologic agents used for HCT preparative regimens with speciﬁc focus on the obese patient population.
The review found that dose adjustments for obesity have, to date, been based empirically or extrapolated
from published data in the nontransplantation patient population. As a result, the Committee determined
that clear standards or dosing guidelines are unable to be made for the obese population because Level I and II
evidence are unavailable at this time. Instead, the Committee provides a current published literature review
to serve as a platform for conditioning agent dose selection in the setting of obesity. A necessary goal should
be to encourage future prospective trials in this patient population because further information is needed to
enhance our knowledge of the pharmacokinetics and pharmacodynamics of conditioning agents in the
setting of obesity.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION are deﬁned using weight divided by height squared are not
Over the past 50 years in the United States, the average
weight in adults has increased by 11 kg, whereas the average
increase in height has approximated only 2 cm [1]. The
prevalence of obesity in children and adolescents ages 2 to
19 years has increased from 5% in 1971 to 16.9% in 2010 [2,3].
This has led to an increasing prevalence of high body mass
index (BMI) categories that are used by the World Health
Organization to deﬁne individuals who are “overweight”
(BMI 25 to 29.9 kg/m2), “obese” (BMI  30 to 39.9 kg/m2), or
“severely obese” (BMI  40 kg/m2) [1]. BMI categories are
considered a rough guide because they may not correspond
to the same body fat percentage in different individuals. For
similar reasons, particularly because of physiological changes
that occur during normal development, BMI estimates thatedgments on page 605.
quests: Joseph Bubalo, PharmD, Oregon
pital, 3181 SW Sam Jackson Park Road,
du (J. Bubalo).
2014 American Society for Blood and Marrow
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olescents, Centers for Disease Control and Prevention growth
charts are used to determine the corresponding BMI-for-age
and sex percentile. Thus, “overweight” corresponds to a BMI
 85th percentile and “obese” corresponds to a BMI  95th
percentile [4]. Rates of obesity vary by country and ethnicity.
In the United States, more than one third of adults (37.5%)
and approximately 17% (or 12.5 million) of children and ad-
olescents are obese [5]. Understandably, dosing chemo-
therapy in obese cancer patients is a common issue.
Chemotherapy used as part of conditioning therapy before
hematopoietic stem cell transplantation (HCT) has multiple
purposes. In the autologous setting, the goal is primarily to
reduce tumor burden, but in the allogeneic setting, there is
the additional need for immune modulation to overcome
rejection of the new hematopoietic system. Appropriate
dosing has been considered critical in the myeloablative
conditioning setting because chemotherapy doses were his-
torically increased to levels just below those at which unac-
ceptable rates of fatal side effects occur. Selecting the optimalTransplantation.
Table 1
Obesity Overviews and Recommendations from the Literature
Outcomes Basis Comments Reference
Overall reviews
Patients whose admission TBW was
120%-139% greater than their
age-adjusted BMI had higher NRM
than patients whose TBW was
100%-119% of age-adjusted BMI.
Retrospective review of 473 (72 obese, 32
very obese) consecutive autologous adult
patients with mixed hematologic
malignancies treated between 1988 and
1995 with 7 different regimens. Median
follow-up of 2.3 yrs.
Dosing: dosed on TBW at admission unless
patient was >15 kg above IBW; then they
were dosed on adjusted body weight (40%),
ABW40.
Patients were compared based on their
admission TBW versus their age-adjusted
BMI, which is a nonstandard measurement
system.
Age-adjusted BMI was associated with an
increased NRM in obese patients.
Conclusion
Dose adjustment in obese autologous HCT
patients does not increase risk for disease
relapse.
[23]
No differences in OS between normal
and obese for any patient group;
TRM and relapse risk were greater
in the BMI < 18 group, and relapse
was signiﬁcantly less in the obese
and morbidly obese groups.
Retrospective review of the CIBMTR
database of adult patients (autologous 373
with 85 obese, allogeneic MRD 2041, URD
1801, 654 obese overall) with AML treated
between 1995 and 2004 with unreported
regimens. Compared underweight (BMI <
18), normal (18-25), overweight (>25-30),
obese
(>30-34), and morbidly obese (35).
Median follow-up of 51 to 87 mo.
Dosing: Basis for dosing not reported.
No differences in GVHD between groups.
Unable to assess doses used in conditioning
regimens or body weight used.
Conclusion
Obese individuals derive beneﬁt from and
can be treated safely with HCT.
[24]
Obese patients had equivalent (NS)
OS and PFS but higher infection
rates and more inpatient days
in the ﬁrst year after HCT.
Retrospective review of 325 (46 obese)
allogeneic adult patients with hematologic
malignancies treated before 2010 with
multiple regimens. Obese (BMI > 30) (14%)
were compared with normal (40%) or
elevated BMI [25-  30] (46%). Median
follow-up of 24 mo.
Dosing: Basis for dosing not reported but
BSA was capped at 2.2 m2 regardless of
actual BSA.
Variety of ablative and RIC regimens listed.
Found allogeneic HCT acceptable choice.
Conclusion
Obese patients may be at increased risk for
infection and require a higher level of care
when undergoing allogeneic HCT.
[25]
Obese patients had a shorter
overall survival.
Retrospective review 322 (242 adult and 80
pediatric, 91 obese) allogeneic patients with
hematologic malignancies, aplastic anemia,
or metabolic storage diseases, treated
between 1983 and 1995 with an
unreported chemotherapy regimen.
Survival was 35% versus 20% (P ¼ .0045)
with a median of
262 d (nonobese) and 120 d (obese) follow-
up.
Dosing: neither the conditioning regimen
nor the basis for dosing was recorded.
Relapse-related mortality was not signiﬁ-
cantly different between obese (17%) and
nonobese (23%) (P ¼ .461).
The survival difference was signiﬁcant in
adults but not in a comparison of pediatric
cases and controls.
Conclusion
Obese adults but not pediatric patients may
have shorter nonrelapse-related survival
with allogeneic HCT.
[26]
Toxicity varied by regimen but weight
was predictive for mucositis (low or
high weight) but not GVHD, sepsis,
or SOS. No difference in TRM, PFS, or
OS by weight.
Retrospective review of 262 (52 obese)
adult patients (maximum 60 yrs old) with
hematologic malignancies treated with
multiple regimens before 2009. Only
ablative regimens reviewed and actual body
weights were adjusted per Metropolitan
Life IBW tables for different frame sizes
were used to test the use of large frame
weight in place of TBW in obese individuals.
Median follow-up of 11 to 23 mo, varying
by regimen.
Dosing: If a patient’s TBW was > than the
top weight for their height, then the top
weight in the large frame table was used. If
TBW was < than the highest weight for
their height, then TBWwas used. BSA range,
1.28-2.4 m2.
Conclusion
Obese patients may experience increased
speciﬁc toxicities, but when viewed overall
did not experience increased treatment-
related or relapse-related mortality with
allogeneic HCT.
[27]
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Table 1
(continued)
Outcomes Basis Comments Reference
Obese allogeneic patients have a higher
risk of NRM and inferior survival.
Obese autologous patients have
similar outcomes to nonobese.
Literature review e methods not reported. Dosing: Recommend ABW25 for dosing
weight going forward based upon current
study reports.
Adipose tissue may sequester lipophilic
drugs.
Need more consistent and biologically
relevant deﬁnitions of obesity.
IBW dosing may result in underexposure to
some drugs.
Review based primarily on myeloma/
melphalan studies. Limited basis for other
agents.
Conclusion
Obese allogeneic patients may have a
higher risk for NRM while obese autologous
patients do not appear to. This may be
regimen related.
[4]
Alkylating agentebased reviews
Obese patients had less mucositis and
shorter LOS. No difference in
relapse or survival was reported
between groups.
Retrospective review of 80 (19 in highest
dose/weight quartile) autologous adult
patients with NHL treated between 2001
and 2005 with BEAM (melphalan dose used
as surrogate marker). Median follow-up of
31.4 mo.
Dosing: Dosed upon BSA based on ABW25 if
TBW > IBW.
The actual patient weight versus their dose/
weight quartile is not recorded or
contrasted.
Conclusion
Obese patients may have less toxicity and
similar survival with autologous HCT. May
be regimen speciﬁc.
[28]
Patients with increased BMI had shorter
time to engraftment and no
difference in OS or LFS.
Retrospective review of 1662 adults (258
autologous, 1404 allogeneic, 77 obese) and
576 pediatric (79 autologous, 497
allogeneic, 13 obese) patients with
hematologic malignancies or aplastic
anemia treated between 1985 and 1992
with Bu(16) Cy(120) (TBW), Cy (200)ATG,
CyTBI. Median follow-up of 150 d.
Dosing: majority dosed on TBW; however,
cyclophosphamide, when dosed at 200 mg/
kg over 4 d, was generally dosed at ABW50
based on physician preference. The number
dosed in this manner is not recorded.
Conclusion
Obese adults and pediatrics can be safely
treated with HCT deriving similar survival
outcomes.
[29]
Obese patients have equivalent TRM and
survival to those with normal weight
patients and may have shorter time to
engraftment.
Retrospective review of 192MRD allogeneic
adults (61 obese) with acute leukemia
treated with multiple regimens between
2006-2009. Median follow-up of 15 mo.
Dosing: Chemotherapy was based on TBW
and the primary regimen was Bu(16)
Cy(120).
RRT not reported, other than 1 death due to
VOD.
Conclusion
Obese allogeneic HCT have similar survival
to nonobese.
[30]
Obese patients had decreased mucositis,
peak alkaline phosphatase, and no
survival difference.
Retrospective review of 63 (13 obese)
autologous adults treated before 2003 for
AML with busulfan 16 mg/kg PO plus
etoposide
60 mg/kg  1. Median follow-up not
reported.
Dosing: Dosed on ABW25.
Conclusion
Obese autologous patients may have less
toxicity and equal survival. May be regimen
speciﬁc.
[31]
The risk of death (reduced OS) of an
overweight adult was 2.9 times that
of a nonoverweight individual.
Retrospective review of 121 (28 obese)
adult autologous NHL patients treated
between 1990 and 1997 with either BEAM
or high-dose mitoxantrone and melphalan.
They were compared for outcomes with
BMI < 28 compared with BMI  28.
Dosing: Dosed on TBW with a dose
adjustment for 6 of 9 patients with a BMI
32.
77% had a BMI< 28 and 23% had a BMI 28
with 7 % overall  32.
No signiﬁcant difference was seen in RRT
between groups with a nonsigniﬁcant
decrease in the BMI  28 group.
Conclusion
Exercise caution in treating overweight NHL
patients with autologous HCT as they may
have lower survival.
[32]
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Table 1
(continued)
Outcomes Basis Comments Reference
For melphalan based conditioning, obese
patients had no difference in PFS, OS,
disease progression, or NRM.
However, for melphalan and TBI
regimens obese and severely obese
patients had better PFS, OS, and less
progression but not better NRM.
Retrospective review of the CIBMTR
database of 1087 autologous adults (109
obese, 125 severely obese) treated between
1995 and 2003 with melphalan or
melphalan plus TBI for multiple myeloma.
Median follow-up of 59 to 63 mo.
Dosing: Basis for dosing not reported.
Analysis based on TBW from database
showed reduced dosing of melphalan in
78% of severely obese, 56% of obese, 32% of
overweight, and 11% of normal weight.
There was no effect of dose reduction on
PFS.
Conclusion
Obese autologous patients have similar
survival, but this may be regimen
dependent.
[12]
Obese allogeneic patients had similar
outcomes when compared with
nonobese patients with regard to
mucositis, cardiotoxicity, emesis,
and hyperglycemia.
Nutritional status did not impact
OS, PFS, or 100-day TRM.
Retrospective review of 71 adult allogeneic
HCT patients (11 obese) with hematologic
malignancies or MDS treated between 2003
and 2009 with Bu(12.8 or 16) Cy(120) or
CyBu (numbers of each regimen not
reported). Median follow-up not reported.
Dosing: Dosing was on TBW for normal and
underweight (BMI < 18.5) and based on
ABW25 for overweight (BMI 25 to 29.9) and
obese (BMI  30).
Conclusion
Obese allogeneic patients have similar
levels of toxicity when dosed on adjusted
body weight.
[33]
One and 2-year OS was worse in
overweight children.
Retrospective review of CIBMTR database
based on 1281 pediatric patients (143
overweight) with SAA treated withmultiple
cyclophosphamide-containing regimens
with allogeneic HCT. Median follow-up >2
yrs.
Dosing: Dosing data not provided and no
comment on the effect of dosing on
outcomes.
Other factors affecting survival were race,
region, donor type, conditioning regimen in
related donor HCT, performance score, and
year of HCT.
The impact of obesity on survival should be
part of pretransplantation counseling for
children with SAA.
Conclusion
Obese pediatrics undergoing allogeneic HCT
for SAA may have decreased survival versus
nonobese pediatrics.
[34]
ABW25 indicates IBW þ .25(TBW-IBW); ABW40, IBW þ .4(TBW-IBW); ABW50, IBW þ .5(TBW-IBW); AML, acute myelogenous leukemia; ATG, antithymocyte
globulin; BEAM, carmustine, etoposide, cytarabine, andmelphalan; BMI, body mass index; BSA, body surface area; Bu, busulfan; Bu16, busulfan 16mg/kg PO over
4 days; Bu12.8, busulfan 12.8 mg/kg i.v. at variable dosing frequencies; CIBMTR, Center for International Blood and Marrow Transplant Research; Cy, cyclo-
phosphamide; Cy120, cyclophosphamide 120 mg/kg over 2 days; Cy200, cyclophosphamide 200 mg/kg over 4 days; GFR, glomerular ﬁltration rate; GVHD, graft-
versus-host disease; HCT, hematopoietic cell transplantation; IBW, ideal body weight; LFS, leukemia-free survival; LOS, length of stay; MRD, matched related
donor; NHL, non-Hodgkin lymphoma; NRM, nonrelapse mortality; NS, nonsigniﬁcant; OS, overall survival; PFS, progression-free survival; PO, oral; PTLD, post-
transplantation lymphoproliferative disorder; RIC, reduced-intensity condition; RRT, regimen-related toxicity; SAA, severe aplastic anemia; SOS, sinusoidal
obstruction syndrome; TBI, total body irradiation; TBW, total bodyweight; TRM, treatment-relatedmortality; URD, unrelated donor; VOD, veno-occlusive disease.
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dosing of chemotherapy used before HCT. There is variability
based upon chemotherapy conditioning regimen agents, type
of tumor treated, patient age, patient weight or size, and the
therapeutic intent (myeloablative, reduced intensity without
myeloablation, or autologous with stem cell rescue). With
respect to patient weight, many attempts have been made to
standardize dosing to achieve consistent therapeutic effects,
while ﬁnding an acceptable or manageable level of toxicity in
all patients. This hasmost frequently been attempted through
the application of normalized formulas based upon body
surface area, body weight, or pharmacokinetic- (PK) based
formulas to accommodate for differences in body distribu-
tion, toxic effects, and metabolism between different
chemotherapeutic agents. It is clear that there is no single
dosing parameter for describing the PK of drugs in obese
patients [6]. Other than for busulfan, the methods for dose
adjustment to achieve targeted body exposures for speciﬁc
agents within a preparative regimen are either poorly vali-
dated, not readily available, or both. Moreover, the target
exposure required for optimal therapeutic outcomes can vary
in different patient groups and remains a subject of discus-
sion among transplantation professionals [7-9].The 2012 panel review by the American Society of Clin-
ical Oncology recommended that obese adult cancer
patients, speciﬁcally excluding pediatrics, patients with
hematologic malignancies, and those undergoing HCT,
should be treated with full weight-based chemotherapy
doses. This consensus was reached upon aggregate review of
current data and there was no evidence for increased short-
or long-term toxicity among obese patients who received
full weight-based dose regimens [10]. However, a similar
review has not been conducted among obese patients who
underwent HCT, and previous studies have shown conﬂict-
ing results in obese HCT recipients [11,12]. To address the
need for evidence-based guidelines, the American Society
for Blood and Marrow Transplantation Practice Guideline
Committee conducted a comprehensive review of the liter-
ature to consider, if feasible, a position statement on con-
ditioning chemotherapy dosing in obese HCT recipients. This
report presents the Committee’s recommendations for
addressing this issue.METHODS
A comprehensive review was performed of the PubMed and MEDLINE
library databases between 1946 and June 2012 with hand searching of
Table 2
Dosing Recommendations for HCT Conditioning Agents in the Obese Individual
Agent Suggested Dosing Additional Information
Alemtuzumab Flat dosing in adults based upon regimen selected Addition of this agent to conditioning regimens continues to evolve and there are
currently no data on dose adjustments for obese individuals.
Busulfan Dose on ABW25 in adults (obese and nonobese) receiving per kilogram dosing or BSA
based on TBW for m2 dosing. All regimens >12 mg/kg PO equivalent are recommended
to have PK targeting as appropriate for the disease state. Regimens using doses 12mg/
kg PO equivalent do not have sufﬁcient information to recommend routine PK
monitoring at this time.
Pediatrics should be dosed upon TBW with similar monitoring guidelines.
PK monitoring has reduced SOS/VOD from an occurrence rate of approximately 20% to
less than 5% [35].
AUC/Css targeting varies by regimen.
For BuCy regimens the MTD is 16 mg/kg PO equivalent over 4 d for adults.
For BuFlu and BuFluAlemtuzumab MTD based upon daily AUC have been determined.
Dosing with other combinations of agents is still being determined.
Carboplatin Dose adults on BSA based on TBW. No current literature consensus for dosing carboplatin based on AUC for HCT regimens
or adjustments on dosing during HCT for obese individuals.
Carmustine Dose adults on BSA based on TBWunless>120% IBW then dose on BSA based on ABW25. Pulmonary toxicity>50% at 600mg/m2 with multiple agent regimens. MTD of 1200 mg/
m2 as single agent with 9.5% pulmonary toxicity.
Clofarabine Dose adults and children on BSA based on TBW. Addition of this agent to conditioning regimens continues to evolve and there are
currently no data on dose adjustments for obese individuals.
Cyclophosphamide  Dose on the lesser of TBW or IBW for Cy200.
 For Cy120 dosing can be either IBW or TBW until >120% IBW then dose based on
ABW25. The former method is preferred for adults and the latter is preferred in
pediatrics.
Cytarabine Dose adults and children on BSA based on TBW. Cytarabine dosing generally lower than dose used in leukemia consolidation regimens.
Etoposide Dose adults on ABW25 for mg/kg dosing and BSA based on TBW for BSA based dosing. DLT of mucositis.
Fludarabine Dose adults on BSA based on TBW. Risk factors and effects of chemotherapy on post treatment leukoencephalopathy still
being studied for conditioning regimen doses above 125 mg/m2.
Melphalan Dose adults on BSA based on TBW. DLT of mucositis. Adjustments for age and renal function are still not standardized.
Pentostatin Dose adults on BSA based on TBW. Addition of this agent to conditioning regimens continues to evolve and there are
currently no data on dose adjustments for obese individuals.
Thiotepa Dose adults on BSA based on TBWunless>120% IBW then dose on BSA based on ABW40. Multi-agent MTD is 500-750 mg/m2, single-agent MTD is 900 mg/m2 [36].
Antithymocyte globulin - equine Dose on mg/kg based on TBW. Addition of this agent to conditioning regimens continues to evolve and there are
currently no data on dose adjustments for obese individuals.
Antithymocyte globulin - rabbit Dose on mg/kg based on TBW. Addition of this agent to conditioning regimens continues to evolve and there are
currently no data on dose adjustments for obese individuals.
ABW25 indicates IBW þ .25(TBW-IBW); ABW40, IBW þ .4(TBW-IBW); AUC, area under the curve; Bu, busulfan; BMI, body mass index; BSA, body surface area; Css, concentration at steady state; Cy, cyclophosphamide; Cy120,
cyclophosphamide 120 mg/kg; Cy200, cyclophosphamide 200 mg/kg; DLT, dose-limiting toxicity; Flu, ﬂudarabine; MTD, maximum tolerated dose; PK, pharmacokinetics; PO, oral; SOS, sinusoidal obstruction syndrome; TBW,
total body weight; VOD, veno-occlusive disease.
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J. Bubalo et al. / Biol Blood Marrow Transplant 20 (2014) 600e616 605selected reviews, meeting abstracts, and reference lists from selected and
excluded articles. Articles published after the initial data search were
monitored via Pubmed updates until September 2013. The literature search
was limited to articles in English with human participants (Table 1). MESH
headings and keywords searched were “stem cell transplantation,”
“obesity,” “body size,” and equivalent descriptors.
RESULTS
Based upon this review, the committee found they were
unable to draw Level I or II evidence-based conclusions about
how todoseHCTconditioning regimens inobese patients. This
was due to the retrospective nature of reported studies;
limiteddetail fromcase series; insufﬁcient reportingof height,
weight, and BMI; and variable use of PK-based targeting of
chemotherapeutics. Although the literature primarily sup-
ports that obesity is not a barrier to good clinical HCT out-
comes, the data are insufﬁcient to determine optimal drug
doses for conditioning obese individuals. This is complicated
further in infancy and childhood by dramatic age-related
differences in drug disposition and because known relation-
ships between age and physiological processes might not still
hold when obesity is also present [13,14].
Moreover, despite historic knowledge of maximum
tolerated doses based on human tissue tolerability, current
research reports provide evidence that known dose limits are
not always taken into consideration. This is particularly
apparent with the expanding number of nonablative condi-
tioning protocols that report patient exposures to doses that
meet or exceed those historically shown to cause harm [15].
Given the limitations of existing literature noted above
and insufﬁcient evidence to propose Level I or II recom-
mendations, the committee decided instead to summarize
current knowledge to support current practice and provide a
basis for future research in this area. With this intent, we
report the following consensus recommendations on con-
ditioning therapy dosing as a basis to support the assessment
and development of conditioning studies in obese patients
(Table 2). Appendix 1 provides supporting data, which con-
tains, when available, dosing information for obese patients,
in addition to the general population. It also contains
selected supporting or descriptive information to help
medical providers assess the applicability of the dosing in-
formation to their respective patient populations.
It is important to note that the study of obese individuals
has moved beyond the listing of actual versus ideal body
weight, lean or fat-free weight, BMI, gender, and ethnicity-
based weight indexes, and other measures based heavily
upon a variety of mathematical models [1]. In an effort to
discern the larger but healthy, or “ﬁt” individual, there are
now models which use radiographic techniques, bioelectric
impedance, fat distribution assessment, and other methods
that may be technically more accurate in assessing an in-
dividual’s body composition but are of undocumented
applicability when it comes to the dosing of individual drugs
[1]. Given the current limited reporting of patient physical
demographics (frequently just age and gender), these newer
and possibly more accurate methods of weight assessment
are not yet validated for use with medication dosing and,
thus, not applicable for daily use.
The recommendations for dosing chemotherapeutic agents
in HCT conditioning regimens are described in Table 2 and are
based on the articles listed in Table 1 and Appendix 1. The
following standardized deﬁnitions were used: overweight:
BMI 25 to< 30 kg/m2; obese: BMI 30 to 34 kg/m2; morbidly
obese: BMI 35 to 39 kg/m2; and extremely obese: BMI 40 kg/
m2. It should also be noted that, although pediatric data aremore limited than adult data, they have been provided when
adequate supporting information was available.
CONCLUSIONS
Reviewof the literature provides the following tenetswhen
dosing antineoplastics for disease control and prevention of
graft rejection in the setting of autologous and allogeneic HCT:
 In both the ablative and nonablative settings, some drug
doses have been titrated beyond myelosuppression to
the next dose-limiting toxicity. For example, cyclo-
phosphamide is dosed at 4 to 8 times the doses seen in
conventional antineoplastic therapy, such that cardiac
toxicity becomes the dose-limiting factor [16].
 The dose-limiting toxicity of each agent within a con-
ditioning regimen may vary, depending on 1 or more
other agents with which it is combined. For example,
carmustine toxicity occurs at a signiﬁcantly different
dose in combination versus as a single agent [17,18].
 Obese patients often have comorbidities that further
affect drug disposition or tolerance.
 Supportive care advances and current PK practices have
allowed further dose advancement and have dimin-
ished the occurrence of some previously common tox-
icities associated with HCT for some medications,
primarily busulfan [19-22].
 To help advance the ﬁeld, we suggest that journals
mandate that future research publications on this topic
and those that describe conditioning regimens incor-
porate the critical parameters of height, weight, body
surface area, and BMI to provide more meaningful
clinical outcomes assessments.
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Appendix 1
Evidence for Chemotherapy Dose Adjustment
Agent Dosing Basis Patient Population Comments Reference
Alemtuzumab Same dose regardless of BSA
(20 mg d  5 d).
Phase I/II study of clofarabine, melphalan, and alemtuzumab in
82 allo adult patients with mixed hematologic malignancies,
MPD, or MDS.
Treatment period before 2012 but was not reported speciﬁcally.
Median follow-up was 25 mo.
Body weight parameters not provided.
RRT-related mortality of 19% in ﬁrst 100 d.
Multiple cases of renal toxicity, sepsis (4), cardiac deaths (3 with
1 in an obese patients), and 1 irreversible encephalopathy.
No SOS/VOD.
[37]
Busulfan Dosed on TBW. Retrospective review of 1662 adults (258 auto, 1404 allo) and
576 pediatrics (79 auto, 497 allo) patients with hematologic
malignancies or aplastic anemia treated between 1985 and
1992 with Bu(16) Cy(120 or 200), CYATG, or CYTBI (TBW) at a
single institution.
Distribution was <95% IBW (187), 95%-145% IBW (1398), and
>145% IBW (77).
Median follow-up of 150 d.
Patients >145% versus 95% to 145% had shorter time to
engraftment and no difference in OS or DFS. Those with <85%
IBW did worse.
77 obese adults and 13 obese children in sample.
[29]
Busulfan Dosed on TBW. Retrospective review of 192 allo adults (61 obese) with acute
leukemias treated with multiple regimens between 2006
and 2009.
Patients conditioned with Bu (16) Cy(120) (on TBW) for MRD
HCT.
Median age 28 (15-57).
Median follow-up of 15 mo.
Increased BMI had shorter time to engraftment and no
difference in OS or LFS.
No signiﬁcant difference in 1-yr TRM between normal weight
and obese patients.
Overweight/obese deﬁned as BMI >25. No information on level
of obesity.
RRT not reported, other than 1 death due to VOD.
[30]
Busulfan Dosed on ABW25. Retrospective review of 63 auto adults treated before 2003
(actual time period not reported) for AMLwith Bu 1mg/kg/dose
PO for 16 doses plus E 60 mg/kg for 1 dose.
Median follow-up not reported.
Observed decreased mucositis and peak alkaline phosphatase in
the obese patients with no survival difference.
Small patient groups, 13 patients  130% IBW were compared
with 19 patients at 97%-103% IBW.
[31]
Busulfan Dosed based on the lesser of TBW
or IBW. -Based on institutional
practice and ABW (adjustment not
stated) could be used.
61 adult allo patients with mixed hematologic malignancies or
MDS treated between 1996 and 1997 conditioned with Bu .8
mg/kg/dose i.v. every 6 h for 16 doses without targeting PK and
Cy 60 mg/kg for 2 doses.
Median follow-up 28 mo.
Patient weight parameters not provided.
5 cases SOS (8.2%, 2 fatal), 44% grade 2, and 26% grade 3
mucositis, 1 interstitial pneumonitis, 2 pneumonia with DAH.
[38]
Busulfan Dosed on TBW up to 120% of IBW
then dosed on ABW50.
36 adult allo patients with CML treated between 1996 and 2001
with BuCy2.
Bu 16 mg/kg PO over 4 d targeted to 1250 mmol/min  20% and
Cy 60 mg/kg for 2 d.
Median follow-up not reported.
Stated AUC target of 950-1520 mmol/min is optimal for BuCy2.
No VOD, 47% grade 2/3 mucositis, 17% grade 3 diarrhea.
Weight parameters for patients not reported.
[39]
Busulfan Dosed on TBW and used test dose for
PK targeting for obese and nonobese.
Retrospective chart review of 68 pediatric allo HCTs with a
mixture of malignant and nonmalignant disorders treated
between 2003 and 2008.
BuFluATG(r) or BuFluECP dosed on TBWwith single daily i.v. Bu
dose given based upon the Bu test dose PK to target 4000 to
5000  800 mmol/min. Bu test dose of .8 mg/kg infused over 3 h
5-7 d before HCT conditioning, targeting an AUC of 1000
micromole/min.
Median follow-up not reported.
Dosing needs to be PK based for pediatrics.
32% of the children were obese as deﬁned by >85th percentile
of age adjusted BMI.
The lowest dose/kg and lowest Bu clearance were observed in
obese, thus requiring lower Bu doses.
RIC regimens used with no toxicity data provided.
[40]
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Busulfan Dosed on the lesser of IBW or TBW
unless >120% IBW then ABW25 at
FIRST site and all patients received
Bu and Cy doses based on ABW25
at a SECOND treatment site.
382 adults with NHL treated between 1992 and 1998 with auto
HCT conditioned with Bu 1 mg/kg/dose PO for 14 doses,
E 60 mg/kg for 1 dose, and Cy 60 mg/kg/d for 2 doses.
Median follow-up 33 mo.
2.9% SOS/VOD.
Stated that use of ABW minimized differences in clearance
between obese and nonobese.
Called for studies to start reporting body size units to allow
meaningful comparison of patient data.
26 obese patients and 248 that met ABW dosing criteria.
[41]
Busulfan Dosed patients at .44- 1.8 mg/kg
TBW PO every 6 h for 4 d with PK
on the 5th and 9th doses.
279 adolescent and adult (ages 13 to 60) allo and auto
(breakdown not reported) patients treated at a single center
between 1992 and 1996 for hematologic malignancies, breast
cancer, ovarian cancer, or MDS with PK-targeted
Bu PO Q 6 h  4 d (16 doses).
Compared underweight, normal, obese, and severely obese
patients for HCT for a variety of cancers.
Additional agents or TBI could be given after Bu but not before it.
Median follow-up not reported.
No patients <12 yrs old.
Grade III/IV RRT seen related to high Bu exposure.
Graft rejection related to low Bu exposure.
Recommended dosing adult patients on ABW25 to remove
variability based on body size; however, dosing based on AUC or
Css is required to compensate for other metabolic and genetic
variables.
Weight categories deﬁned as underweight (BMI < 18 [n ¼ 7],
normal (BMI 18-26.9 [n ¼ 173]), obese (BMI 27-35 [n ¼ 89]),
severely obese (BMI > 35 [n ¼ 10]).
[42]
Busulfan Dosed on BSA, based on TBW, some
patients dosed with PK targeting
102 adult autoHCT patients with advanced lymphoid
malignancies treated between 2005 and 2008 with Bu
130 mg/m2 i.v. for 4 d or to target 5000  12% mmol/min
d and melphalan 70 mg/m2 for 2 d.
Median follow-up of 34 mo.
1 case SOS and no grade IV toxicities.
No patient weight parameters reported.
[43]
Busulfan Dosed on TBW and adjusted to meet
target AUC based on phase I study
criteria starting at a daily AUC of
4800 mmol/min.
Phase 1 trial of 36 adult allo HCT treated between 2005 and 2007
for a variety of hematologic malignancies.
Conditioning regimen contained Bu at either 3.2 mg/kg i.v. or
adjusted dose daily based on a .5 mg/kg test dose within 8 d of
starting plus ﬂudarabine 25 mg/m2/d and alemtuzumab 20 mg/
d  5 d.
MTD of 5800 mmol/min/L with DLT of 62.5% SOS/VOD at AUC of
6800 mmol/min/L.
No patient weight parameters reported.
SOS may be associated with peak busulfan level.
[7]
Busulfan Dosed on TBW calculated BSA
with PK targeting.
Phase I trial of 72 adult MMUD allo HCT treated between 2005
and 2010. Bu targeted daily AUC levels: group 1 (6000  600),
group 2 (7500  750), or group 3 (9000  900) mmol/min with
initial dose of 170 mg/m2, 180 mg/m2, or 220 mg/m2/daily i.v.
respectively for 4 d.
Patients also received Flu 40 mg/m2/d for 4 d, and ATG(r) 3.25
mg/kg/d for 2 d.
Minimum follow-up of 10 mo.
No patient weight parameters provided.
SOS/VODwas the DLT with 0 at level 1, 7% at level 2, and 100% at
level 3.
No difference in NRM between levels 1 and 2.
[8]
Busulfan Dosed on IBW with PK targeting in a
subgroup of 12 patients.
70 adult allo patients with a variety of hematologic disease
states and MDS treated between 1999 and 2001.
Conditioned with Bu 3.2 mg/kg i.v. for 4 d plus Flu 50 mg/m2 for
5 d plus ATG(r) 4.5 mg/kg over 3 d.
Median follow-up 16 mo.
1 Bu-related seizure, 70% grade II stomatitis, 74% ALT increases
with 1 SOS, no reporting of cognitive/neurotoxic effects of
ﬂudarabine.
Mean daily Bu AUC of 4900-5000 mmol/min.
No patient weight parameters reported.
[44]
Busulfan Dosed on IBW. 50 adult (16-50 yrs old) allo patients with varied leukemias
treated between 1984 and 1986.
Conditioned with Bu 1 mg/kg PO for 16 doses plus Cy 60 mg/kg
for 2 doses.
Follow-up 6 to 36 mo with no median reported.
1 case of SOS, 5 cases severe hemorrhagic cystitis. Most
symptoms reported descriptively and not graded.
No patient weight parameters reported.
[45]
(continued on next page)
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Appendix 1
(continued )
Agent Dosing Basis Patient Population Comments Reference
Busulfan Dosed on ABW25 if > 130% IBW and
lesser of TBW or IBW if  130% IBW.
Retrospective review of 294 adult auto patients treated between
1999 and 2010 with BuCyE for lymphoma compared PK-guided
results of oral Bu versus 2 i.v. Bu schedules.
BMI’s ranged as high as 62 and BMI was not associated as a
change in OS.
16 mg/kg PO or 12.8 mg/kg i.v. targeted to AUC 20,000
(18,400-21,600) mmol/min off ﬁrst dose PK.
Median follow-up varied by group from 311 to 1565 d.
100-d RRT 2.1%-3.5% across groups and causes of death not
listed.
BMI range and average shown but not percent of obese patients
and no obese subset analysis.
PK-guided Bu is equivalent in outcomes whether PO-16 doses,
i.v.-16 doses, or i.v.-4 doses if guided to the same exposure
target.
[46]
Busulfan Dosed on ABW25. Retrospective literature review of multiple public databases
with unclear search parameters.
Single obese adult allo HCT CML patient treated with Bu(12.8)
Flu(150) ATG(e)(60) versus 9 normal-weight patients treated at
the same institution.
Dates of patient therapy not reported.
Duration of follow-up unreported.
Busulfan AUC target (900-1500 mmol/min) from ﬁrst dose PK
sampling showed similar plasma concentrations compared with
normal-weight patients on the same regimen.
[47]
Busulfan Dosed on TBW. Retrospective review of 48 pediatric allo and auto patients with
malignant and nonmalignant disorders treated between 1997
and 2001 with oral Bu(16) plus 1-2 additional agents.
Duration of follow-up not reported.
Patients were 0.4-18 years old and BSA of 0.29-2 m2.
Individual patient parameters not correlated with patient
weight.
Best correlation was between PK parameters and dosing on
TBW.
[48]
Busulfan Dosed on ABW25 for per kilogram
dosing or actual TBW-based
BSA if BSA-based.
Retrospective population PK model created from 5 studies of
127 adult patients with mixed hematologic malignancies and
MDS treated between 1996 and 1997 treated with Bu(12.8 mg/
kg) Cy(120).
Model contains 6 underweight, 71 normal- weight, 39 obese,
and 11 severely obese people.
Follow-up not recorded.
I.V. busulfan has the most consistent PK with target levels when
dosed on ABW25 for per kilogram dosing and BSA based on
TBW.
Limited sampling strategies are effective for adjusting busulfan
dosing to achieve target drug levels.
[49]
Busulfan Dosed on TBW. Prospective evaluation of 24 pediatric patients with malignant
hematologic or nonmalignant disorders conditioned before
2007 for allo HCT with Bu(12.8 or 16) Cy(200). Busulfan was
dosed to achieve target AUC of 950-1350 mmol/min.
Duration of follow-up not reported.
Busulfan was dosed i.v. at 1 mg/kg  4 yrs old and .8 mg/kg >4
years old, then adjusted to target AUC (1 patient not adjusted).
No weight parameters for patients were reported, unclear if
sample contained obese patients.
21% VOD observed.
Suggested dosing based on PK model created is 1.1 mg/kg for
 12 kg and .8 mg/kg for >12 kg patients.
[50]
Carboplatin Dosed on BSA based on the lesser
of IBW or TBW.
Retrospective review of 117 adults and childrenwith a variety of
solid tumors (mainly breast tumors in adults) treated with and
auto HCT between 1994 and 1999.
Conditioned with Cy 2000 mg/m2 plus carboplatin 600 mg/m2
daily for 3 d.
Median follow-up not reported.
AUCwas calculated retrospectively for each individual using the
Calvert formula.
Daily AUC >7 was associated with higher levels of  grade 2
nonhematologic toxicity.
Weight parameters not reported.
Number of pediatric patients not reported.
[51]
Carboplatin Dosed patient on TBW. Single adult auto breast cancer patient (BMI 47) case report
treated before 2002 (date not reported) with Cy 1000 mg/m2/
d plus thiotepa 80 mg/m2/d plus carboplatin AUC 3.25/d for 4 d.
PK drug values were compared with normal population using
PK targeting.
Duration of follow-up not reported.
No speciﬁc toxicity or clinical data provided.
Suggested dosing in obese was carboplatin AUC based on
ABW 50.
Comparator population data derived from both HCT and
non-HCT population data.
[52]
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Carboplatin Dosed on BSA based on TBW. 46 adults with a variety of solid tumors treated before 2001
(actual dates not reported) with single or multiple courses of
either Cy 1500mg/m2 plus carboplatin 400mg/m2 plus thiotepa
120 mg/m2 daily for 4 d or the same agents at two-thirds the
dose.
Median follow-up not reported.
Relationships were identiﬁed between elevated transaminases
and thiotepa and TEPA AUC, mucositis, and TEPA AUC,
ototoxicity and carboplatin AUC, and a trend towards
4-hydroxycyclophosphamide AUC and VOD.
No patient weight parameters reported.
[53]
Carmustine Dosed on BSA based on TBW.
If TBW > IBW, then dosed on BSA
based on ABW25.
Retrospective review of 80 (19 in highest dose/weight quartile)
adult auto patients with NHL treated between 2001 and 2005
with BEAM (melphalan dose used as surrogate marker).
Median follow-up of 31.4 mo.
Care performed primarily as an outpatient.
BSA-based melphalan doses >3.6 mg/kg based on TBW
signiﬁcantly increased rates of grade III/i.v. mucositis and
increased lengths of hospital stay were seen.
Dose correlation with BMI or body habitus not performed with
quartile placement.
Obese patients had less mucositis and shorter LOS, and no
difference in relapse or survival.
[28]
Carmustine Dosed on BSA based on TBW up to
120% IBW, then ABW50.
85 adult female auto patients being treated before 2001 (actual
dates not reported) for breast cancer treated with Cy 1875 mg/
m2/d for 3 d plus cisplatin 165 mg/m2 over 3 d plus carmustine
600 mg/m2 for 1 d. 25 patients were >120% IBW.
Median follow-up not reported.
Obese patients had signiﬁcantly lower cisplatin concentrations
and lower, but not signiﬁcantly, Cy concentrations with similar
carmustine concentrations.
Carmustine concentrations in those with pulmonary toxicity
were not different than those who did not.
No patients were morbidly obese, >2 times IBW.
[54]
Carmustine Dosed on BSA based on TBW. 29 adults with varied solid tumors treated before 1986 (actual
dates not reported) on a phase I auto study of escalating doses of
Cy, cisplatin, and carmustine.
No median follow-up reported.
MTD of carmustine when dosed with cyclophosphamide and
cisplatin is 600 mg/m2.
DLT is VOD/SOS for the combination.
Patient weight parameters not reported.
[17]
Carmustine Dosed on BSA based on TBW. 143 adult and pediatric patients with refractory solid and
hematologic cancers treated between 1978 and 1980 with
escalating doses of carmustine with auto marrow rescue.
Median follow-up not reported, 4 patients remained alive when
article written.
MTD of 1200 mg/m2 due to lung and liver toxicity. 9.5%
pulmonary toxicity.
No patient weight parameters reported.
Number of pediatric patients not reported.
[18]
Carmustine Dosed on BSA based on TBW. 35 adults with a variety of solid tumors treated between 1978
and 1980 with escalating dose carmustine with auto marrow
rescue in a phase I trial.
No median follow-up reported.
Visceral toxicities (hepatic and pulmonary) are dose limiting
above 600 mg/m2.
No patient weight parameters reported.
[55]
Clofarabine Dosed on BSA based on TBW.
40 mg/m2/d for 5 d.
Phase I/II study of clofarabine, melphalan, and alemtuzumab in
82 allo adult patients with mixed hematologic malignancies,
MPD, or MDS.
Treatment period was before 2012 but was not reported
speciﬁcally.
Median follow-up was 25 mo.
Body weight parameters not provided.
RRT-related mortality of 19% in ﬁrst 100 d.
Multiple cases of renal toxicity, sepsis (4), cardiac deaths (3 with
1 in an obese patient), and 1 irreversible encephalopathy.
No SOS/VOD.
[37]
Cyclophosphamide Dosed on TBW except Cy 200 mg/kg,
which was generally dosed on
ABW50 based on physician preference.
The number dosed in this
manner is not recorded.
Retrospective review of 1662 adults (258 auto, 1404 allo) and
576 pediatric (79 auto, 497 allo) patients with hematologic
malignancies or aplastic anemia treated between 1985 and
1992 with Bu(16) Cy(120 or 200), CYATG, or CYTBI (TBW) at a
single institution.
Distributed as < 95% IBW (187), 95%-145% IBW (1398), and
> 145% IBW (77).
Median follow-up 150 d.
Patients > 145% versus 95%-145% had shorter time to
engraftment and no difference in OS or DFS. <85% IBW did
worse.
77 obese adults and 13 obese children in sample.
[29]
(continued on next page)
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Appendix 1
(continued )
Agent Dosing Basis Patient Population Comments Reference
Cyclophosphamide Dosed on TBW. Retrospective review of 192 allo adults (61 obese) with acute
leukemias treated with multiple regimens between 2006
and 2009.
Patients conditioned with Bu (16) Cy(120) for MRD HCT.
Median age 28 (15-57).
Median follow-up of 15 mo.
Increased BMI had shorter time to engraftment and no
difference in OS or LFS.
No signiﬁcant difference in 1 year TRM between normal weight
and obese patients.
Overweight/obese deﬁned as BMI >25. No information on level
of obesity.
RRT not reported, other than 1 death due to VOD.
[30]
Cyclophosphamide Dosed based on the lesser of
TBW or IBW.
61 adult allo patients with mixed hematologic malignancies or
MDS treated between 1996 and 1997 conditioned with Bu .8
mg/kg/dose i.v. every 6 h for 16 doses without targeting PK and
Cy 60 mg/kg/d for 2 doses.
Median follow-up 28 mo.
Patient weight parameters not provided.
5 cases SOS (8.2%, 2 fatal), 44% grade 2, and 26% grade 3
mucositis, 1 interstitial pneumonitis, 2 pneumonia with DAH.
[38]
Cyclophosphamide Dosed on the lesser of TBW or IBW. 36 adult allo patients with CML treated between 1996-2001
with BuCy. Bu 16 mg/kg PO over 4 d targeted to 1250 mmol/min
 20% and Cy 60 mg/kg/d for 2 d.
Median follow-up not reported.
Stated AUC target of 950-1520 mmol/min is optimal for BuCy2.
No VOD, 47% grade 2/3 mucositis, 17% grade 3 diarrhea.
Weight parameters for patients not reported.
[39]
Cyclophosphamide Dosed on the lesser of IBW or TBW
unless >120% IBW, then ABW25 at
FIRST site and all patients received Bu
and Cy doses based on ABW25 at a
SECOND treatment site.
382 adults with NHL treated between 1992 and 1998 with auto
HCT conditioned with Busulfan 1 mg/kg/dose PO for 14 doses, E
60 mg/kg for 1 dose, and Cy 60 mg/kg/d for 2 doses.
Median follow-up 33 mo.
2.9% SOS/VOD.
Stated that use of ABW minimized differences in clearance
between obese and nonobese.
Called for studies to start reporting body size units to allow
meaningful comparison of patient data.
26 obese patients and 248 that met ABW dosing criteria.
[41]
Cyclophosphamide Dosed on IBW. 50 adult (16-50 yr old) allo patients with leukemias treated
between 1984 and 1986.
Conditioned with Bu 1 mg/kg/dose PO for 16 doses plus Cy
60 mg/kg/dose for 2 doses.
Follow-up 6 to 36 mo with no median reported.
1 case of SOS, 5 cases severe hemorrhagic cystitis. Most
symptoms reported descriptively and not graded.
No patient weight parameters reported.
[45]
Cyclophosphamide Dosed on TBW if  130% IBW and
ABW50 if >130% IBW.
Retrospective review of 294 adult auto patients treated between
1999 and 2010 with BuCyE for lymphoma compared PK-guided
results of oral Bu versus 2 i.v. Bu schedules.
BMI’s ranged as high as 62 and BMI was not associated with
changes in OS.
16 mg/kg PO or 12.8 mg/kg i.v. targeted to AUC 20,000
(18,400-21,600) mmol/min/d with ﬁrst dose PK.
Dosed Cy at 60 mg/kg/d on d -3 and -2.
Median follow-up varied by group from 311 to 1565 d.
100-d RRT 2.1%-3.5% across groups and cause of death not listed.
BMI range and average shown but not percent of obese patients
and no obese subset analysis.
PK guided Bu is equivalent in outcomes whether PO-16 doses,
i.v.-16 doses, or i.v.-4 doses if guided to the same exposure
target.
[46]
Cyclophosphamide Dosed on TBW. Single adult auto breast cancer patient (BMI 47) case report
treated before 2002 (date not reported) with Cy 1000 mg/m2/
d plus thiotepa 80 mg/m2/d plus carboplatin AUC 3.25/d for 4 d.
PK drug values compared with normal population using PK
targeting.
Duration of follow-up not reported.
No speciﬁc toxicity or clinical data provided.
Suggested dosing in obese with Cy on ABW40-based BSA.
Population data derived from HCT and non-HCT population
data.
[52]
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Cyclophosphamide Dosed with BSA based on TBW up to
120% IBW then ABW50.
85 adult female auto patients being treated before 2001 (actual
dates not reported) for breast cancer treated with Cy 1875 mg/
m2/d for 3 d plus cisplatin 165 mg/m2 over 3 d plus carmustine
600 mg/m2 for 1 d. 25 patients were >120% IBW.
Median follow-up not reported.
Obese patients had signiﬁcantly lower cisplatin concentrations
and lower, but not signiﬁcantly so, Cy concentrations with
similar carmustine concentrations.
Carmustine concentrations in those with pulmonary toxicity
were not different than those who did not.
No patients were morbidly obese, deﬁned as >2 times IBW.
[54]
Cyclophosphamide Dosed on BSA based on TBW. 29 adults with solid tumors treated before 1986 (actual dates
not reported) on a phase I auto study of escalating doses of Cy,
cisplatin, and carmustine. No median follow-up reported.
MTD of carmustine when dosedwith Cy and cisplatin is 600mg/
m2.
DLT is VOD/SOS for the combination.
Patient weight parameters not reported.
[17]
Cyclophosphamide Dosed on TBW. 80 adults and pediatrics treated between 1972 and 1985 with
allo HCT for nonmalignant conditions.
Conditioned with Cy200 mg/kg or Bu(16) Cy(200) þ ATG.
Median follow-up not reported.
17% cardiotoxicity within 10 d of Cy infusion, 43% fatal.
DLT for 4-d regimen with or without Bu.
Primarily an adult issue and suggested not to exceed 1.55 g/m2
in adults.
Weight parameters for patients not reported.
[16]
Cyclophosphamide Dosed on TBW. 196 adult and pediatric (9 < 20 years old) patients with CML
treated between 1985 and 1994 with an allo HCT conditioned
with TBI 1350 plus Cy 120 mg/kg over 2 d.
Median follow-up of 5 yr.
No RRT reported or TRM due to organ failure reported.
Increased body weight index increased risk of death 1.6 times.
14% >125% IBW and 9% >140% IBW.
Unclear if the obese patients were adult or pediatric.
[56]
Cyclophosphamide Dosed on TBW. Retrospective review of 54 (9 obese) adult patients with AML
treated between 1981 and 1999 with an auto HCT.
Conditioned with Bu (16mg/kg over 4 d) Cy 120mg/kg over 2 d.
Median follow-up 76.5 mo.
TRM obese 33% (n ¼ 3) and 8% (n ¼ 3) nonobese. Speciﬁc
toxicities not provided.
Overall survival at median 76.5 mo of 0.22 obese versus 0.63
nonobese (P ¼ .012).
[57]
Cyclophosphamide Dosed on TBW. 12 adult patients with solid tumors treated before 1975 (actual
dates not reported) without auto rescue given Cy 60 mg/kg/d 
2 d.
Median follow-up not reported.
33% cardiac toxicity; none fatal.
No weight parameters reported.
[58]
Cyclophosphamide Dosed on TBW. Retrospective review of 61 adult and pediatric patients with SAA
treated between 2006 and 2011 with an allo URD HCT on the
BMTCTN 0301 clinical trial.
Conditioned with Cy at the 150 mg/kg, 100 mg/kg, 50 mg/kg, or
0 mg/kg dosing levels in addition to ATG(r) 3 mg/kg/d or ATG (e)
30 mg/kg/d for 3 d plus ﬂudarabine 30 mg/m2/d for 4 d, and TBI
200 cGy for 1.
Median follow-up not reported.
Phase I/II trial resulted in 7 of 14 patient deaths at the 150-mg/
kg dose. 2 of pulmonary failure, 2 of ARDS, 1 multiorgan failure,
1 cardiac failure, and 1 viral infection.
Ages 9-61 (2 children and 5 adults).
Weight parameters not shown.
[59]
Cyclophosphamide Dosed on ABW25. Retrospective review of 72 adults with CML treated with
Cy120TBI allo HCT between 1992 and 1999.
Median follow-up duration unclear, followed through d þ18 for
mucositis.
Weights up to 132 kg and BMI up to 42.7 treated but number of
obese patients not reported.
BMI >25 was associated with increased risk for oral mucositis.
[60]
Cytarabine and etoposide
in BEAM regimen
Dosed on BSA based on ABW25. Retrospective review of 80 (19 in highest dose/weight quartile)
auto adult patients with NHL treated between 2001 and 2005
with BEAM (melphalan dose used as surrogate marker).
Median follow-up of 31.4 mo.
Care performed primarily as an outpatient.
At BSA-based melphalan doses >3.6 mg/kg based on TBW
signiﬁcantly increased rates of grade III/IV mucositis and
increased lengths of hospital stay were seen.
Dose correlation with BMI or body habitus not performed with
quartile placement.
Obese patients had less mucositis and shorter LOS, and no
difference in relapse or survival.
[28]
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Appendix 1
(continued )
Agent Dosing Basis Patient Population Comments Reference
Etoposide Dosed adult patients on ABW25 for E. Retrospective review of 63 auto adults treated before 2003
(actual time period not reported) for AML with Bu16 plus E 60
mg/kg for 1 dose.
Median follow-up not reported.
Observed decreased mucositis, peak alkaline phosphatase in the
obese patients with no survival difference.
Small patient groups, 13 patients  130% IBW were compared
with 19 patients at 97%-103% IBW.
[31]
Etoposide Dosed adult patients on TBW if  130%
IBW and ABW50 if >130% IBW.
Retrospective review of 294 adult auto patients treated between
1999 and 2010 with BuCyE for lymphoma compared PK-guided
results of oral Bu versus 2 i.v. Bu schedules. BMI’s ranged as high
as 62 and BMI was not associated with changes in OS.
16 mg/kg PO or 12.8 mg/kg i.v. targeted to AUC 20,000
(18,400-21,600) mmol/min off ﬁrst dose PK.
Dosed etoposide at 10 mg/kg on d 4, 3, and 2.
Median follow-up varied by group from 311 to 1565 d.
100-d RRT 2.1-3.5% across groups and cause of death not listed.
BMI range and average shown but not percent of obese patients
and no obese subset analysis.
PK-guided Bu is equivalent in outcomes whether PO-16 doses,
i.v.-16 doses, or i.v.-4 doses if guided to the same exposure
target.
[46]
Etoposide Dosed on TBW. 90 adult and pediatric AML patients (28 auto, 62 allo) treated
between 1991 and 1998 conditioned with Bu16 plus Cy (30 mg/
kg/dose for 2 doses) plus E 30mg/kg/dose versus 45mg/kg/dose
for 1 dose.
Median follow-up of 16 mo.
30 mg/kg preferred due to higher liver toxicity and SOS,
mucositis, infections, interstitial pneumonitis, and overall TRM
in the 45-mg/kg arm.
Number of pediatric patients not reported.
Patient weight parameters not reported.
[61]
Fludarabine Dosed on BSA calculated from TBW. 70 adult allo patients with hematologic malignancies or MDS
treated between 1999 and 2001.
Conditionedwith Bu 3.2mg/kg/d i.v. for 4 d plus Flu 50mg/m2
5 d, ATG(r) 4.5 mg/kg over 3 d. Median follow-up 16 mo.
1 Bu-related seizure, 70% grade II stomatitis, 74% ALT increases
with 1 SOS, no reporting of cognitive/neurotoxic effects of
ﬂudarabine.
Mean daily Bu AUC of 4900-5000 mmol/min.
-No patient weight parameters reported.
[44]
Fludarabine Dosed on BSA based on TBW. Retrospective review of 61 adult and pediatric patients with SAA
treated between 2006 and 2011 with an allo URD HCT on CTN
0301 clinical trial.
Conditioned with Cy at the 150 mg/kg, 100 mg/kg, 50 mg/kg, or
0 mg/kg dosing levels plus ATG(r) 3 mg/kg/d or ATG(e) 30 mg/
kg/d for 3 d plus ﬂudarabine 30 mg/m2/d for 4 d, and TBI 200
cGy for 1 dose.
Median follow-up not reported.
Phase I/II trial resulted in 7 of 14 patient deaths at the 150-mg/
kg dose. 2 of pulmonary failure, 2 of ARDS, 1 multiorgan failure,
1 cardiac failure, and 1 viral infection.
Ages 9-61 (2 children and 5 adults).
Weight parameters not shown.
[59]
Melphalan Dosed with BSA based on TBW.
If TBW > IBW then dosed on BSA
based on ABW25.
Retrospective review of 80 (19 in highest dose/weight quartile)
adult auto patients with NHL treated between 2001 and 2005
with BEAM (melphalan dose used as surrogate marker).
Median follow-up of 31.4 mo.
Care performed primarily as an outpatient.
At BSA-based melphalan doses > 3.6 mg/kg based on TBW
signiﬁcantly increased rates of grade III/IV mucositis and
increased lengths of hospital stay were seen.
Dose correlation with BMI or body habitus not performed with
quartile placement.
Obese patients had less mucositis and shorter LOS, and no
difference in relapse or survival.
[28]
Melphalan Dose on BSA based on TBW or other
weight per institutional practice.
197 adult auto HCT patients treated before 2008 (actual dates
not reported) with myeloma (n ¼ 109) or NHL (n ¼ 88)
conditioned with either melphalan 200 mg/m2 or BEAM
chemotherapy respectively.
Patients weighing up to 135 kg were treated but prevalence of
obese patients was not reported.
Oral mucositis prospectively reviewed daily until 30 d after
transplantation. Severe oral mucositis occurred in 46% with
myeloma and 42% with NHL. Severe oral mucositis decreased as
BSA increased resulting in a lower mg/kg melphalan dose.
<4.75 mg and > 5.25 mg/kg had less and more signiﬁcant
mucositis respectively.
[62]
Melphalan Dosed on BSA based on IBW. 716 adult patients with myeloma treated between 2000 and
2007 with auto HCT.
Conditionedwith single-agentmelphalan 200mg/m2 for 1 dose.
100-d mortality declined over time to <1% in last 2 yr.
Patient weights not reported.
RRT not reported.
[63]
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Melphalan BSA based on TBW if  60 kg. BSA
based in ABW40 if >60 kg.
381 adult patients with myeloma treated between 1998 and
2002 with auto HCT.
Conditioned with single-agent melphalan 200 mg/m2 (n ¼ 350)
or 140 mg/m2 (n ¼ 31) for 1 dose.
Patient follow-up 60 d for mucositis.
OS not evaluated.
Dose decreased to 140 mg/m2 if serum creatinine >3.
Recommended dose not be adjusted in obese based on
mucositis end points. 3.4 mg/kg was the break point where
increased rates of grade III/IV mucositis were seen when it was
exceeded.
BMI range 17.4-55 (median 26.6), mg/kg weight and mucositis
decreased as BMI increased.
Maximum weight 160 kg but number of obese patients not
reported.
[64]
Melphalan Dosed on BSA based on TBW or if
obese BSA based on (IBW þ 15 kg þ
ABW40).
89 consecutive outpatient adult myeloma patients treated with
auto HCT between 2001 and 2004 at a cycle dose of 140 (>65 yr
old or decreased performance status, n ¼ 14) or 200 mg/m2
(n ¼ 75). Both doses given over 2 d.
Median duration of follow-up not reported.
Obesity not deﬁned.
Number of obese patients not listed.
No RRT-related deaths.
[65]
Melphalan Dosed on BSA based on TBW. 33 adult (26) and pediatric (7) patients with varied solid tumors
treated between 1980 and 1982 with escalating doses of
melphalan with auto at 120-225 mg/m2/cycle.
Median follow-up not reported.
Single-agent DLT (stomatitis, esophagitis, and diarrhea) at 225
mg/m2.
Suggested 180 mg/m2 over 3 d as the MTD.
No patient weight information provided.
[66]
Melphalan BSA based on TBW. Prospective review of 52 children receiving HCT (allo or auto not
reported) for malignancies before 2004.
Melphalan was dosed in 1 of 12 different regimens with or
without other agents.
Melphalan PK were performed, some with a test dose.
Duration of follow-up not reported.
Melphalan PK varied with concomitant agents, carboplatin
increased AUC and decreased clearance.
Melphalan PK varied and was triphasic (n ¼ 36) or biphasic
(n ¼ 16) depending on the individual.
Weight explained up to 80%-85% of the variability in children’s
PK based on PK parameter.
No patient speciﬁc weight parameters were reported.
[67]
Thiotepa Dosed on BSA based on IBW. 15 adult patients (8 allo and 7 auto) with hematologic
malignancies treated before 1995 (actual dates not reported)
with Bu 1mg/kg/dose PO for 10 doses, Cy 60mg/kg/dose for 2 or
3 d, and 250 mg/m2/dose for 3 d.
Median follow-up not reported.
Maximum RRTworse for patients at IBW than for obese patients
dosed on IBW but similar RRT for obese patients dosed on TBW
or ABW40.
Maximum RRT associated with TEPA peak >1.75 mg/mL and
combined thiotepa and TEPA AUC > 30 mg/h/L. 2 patients had
detectable TEPA 6 d post dosing and had engraftment issues.
Actual RRT not listed.
6 patients were > 120% IBW.
Recommended dosing thiotepa at ABW40 because of lower RRT
seen in obese patients.
[36]
Thiotepa Dosed on TBW. Single adult auto breast cancer patient (BMI 47) case report
treated before 2002 (date not reported) with Cy 1000 mg/m2/
d plus thiotepa 80 mg/m2/d plus carboplatin AUC 3.25/d for 4 d.
PK drug values compared with normal population using PK
targeting.
Duration of follow-up not reported.
No speciﬁc toxicity or clinical data provided.
Suggested dosing in obese patients with thiotepa on ABW
40-based BSA.
Population data derived from HCT and non-HCT population
data.
[52]
Antithymocyte globulin e
equine or rabbit
Dosed onTBW. Retrospective review of 61 adult and pediatric patients with SAA
treated between 2006 and 2011 with an allo URD HCT on
BMTCTN 0301 clinical trial at the 150 mg/kg level plus to ATG 3
mg/kg/d or 30 mg/kg/d for 3 d plus ﬂudarabine 30 mg/m2/d for
4 d plus TBI 200 cGy  1.
Phase I trial resulted in 7 of 14 patient deaths. 2 of pulmonary
failure, 2 of ARDS, 1 multiorgan failure, 1 cardiac failure, and 1
viral infection.
Ages 9-61 (2 children and 5 adults).
Weight parameters not shown.
[59]
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Agent Dosing Basis Patient Population Comments Reference
Antithymocyte
globulin e rabbit
Dosed on TBW. Phase I trial of 72 adult allo MMUD HCT Bu targeted levels 1, 2,
or 3 dosed at 170 mg/m2, 180 mg/m2, or 220 mg/m2/d
respectively for 4 d targeting daily AUC of 6000  600, 7500 
750, 9000  900 mmol/min.
Patients also received ﬂudarabine 40 mg/m2/d for 4 d plus ATG
3.25 mg/kg/d for 2 d.
Minimum follow up of 10 mo.
Noweight parameters provided. SOS/VODwas the DLT with 0 at
level 1, 7% at level 2, and 100% at level 3. -No difference in NRM
between levels 1 and 2.
[8]
Antithymocyte
globulin e rabbit
Dosed on TBW. 70 adult allo patients with a variety of hematologic disease
states and MDS treated between 1999 and 2001.
Conditioned with Bu 3.2 mg/kg for 4 d plus Flu 50 mg/m2 for 5 d
plus ATG(r) 4.5 mg/kg over 3 d.
Median follow-up 16 mo.
1 Bu seizure, 70% grade II stomatitis, 74% ALT increases with 1
SOS, no reporting of cognitive/neurotoxic effects of ﬂudarabine.
Mean daily Bu AUC of 4900-5000 mmol/min.
No patient weight parameters reported.
[44]
ABW indicates adjusted body weight; ABW25, IBW þ .25(TBW-IBW); ABW40, IBW þ .4(TBW-IBW); ABW50, IBW þ .5(TBW-IBW); allo, allogeneic; ALT, alanine aminotransferase; AML, acute myelogenous leukemia; AUC, area
under the curve; auto, autologous; ATG, antithymocyte globulin; ATG(e), antithymocyte globulin equine; ATG(e)60, antithymocyte globulin equine 20 mg/kg/day for 3 days; ATG(r), antithymocyte globulin rabbit; BEAM,
carmustine, etoposide, cytarabine, and melphalan; BMI, body mass index; BMTCTN, Blood and Marrow Transplant Clinical Trials Network; BSA, body surface area, Bu, busulfan; Bu16, busulfan 16 mg/kg PO over 4 days, Bu12.8,
busulfan 12.8mg/kg i.v. at variable dosing frequencies; BuCy2, busulfan 16mg/kg Po plus Cy 120mg/kg for 2 doses; cGy, centigray; Css, concentration at steady state; CML, chronic myelogenous leukemia; Cy, cyclophosphamide;
Cy120, cyclophosphamide 120 mg/kg over 2 days; Cy200, cyclophosphamide 200 mg/kg over 4 days; d, day; DAH, diffuse alveolar hemorrhage; DFS, disease-free survival; DLT, dose-limiting toxicity; E, etoposide; ECP,
extracorporeal photophoresis; Flu, ﬂudarabine; FLU(150), Fludarabine 30 mg/m2/day for 5 days; GFR, glomerular ﬁltration rate; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplant; IBW, ideal body weight; LFS,
leukemia-free survival; LOS, length of stay; mg, milligram; MDS, myelodysplasia; MMUD, mismatched unrelated donor; MPD, myeloproliferative disorder; MRD, matched related donor; MTD, maximum tolerated dose; NHL,
non-Hodgkin lymphoma; NRM, nonrelapse mortality; NS, nonsigniﬁcant; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetic; PO, oral; PTLD, post-transplantation lymphoproliferative disorder; RRT,
regimen-related toxicity; RIC, reduced-intensity conditioning; SAA, severe aplastic anemia; SOS, sinusoidal obstruction syndrome; TBI, total body irradiation; TBW, total body weight; TRM, treatment-related mortality; URD,
unrelated donor; VOD, veno-occlusive disease.
When possible, early-phase studies were chosen to illustrate the doses associated with MTD and DLT to facilitate the assessment for known MTD when reviewing a new protocol. Combination regimens often result in different
toxicity proﬁles and doses to achieveMTD and DLT than those in single-agent regimens. Monoclonal and polyclonal antibodies are generally dosed on TBWor given as a ﬂat dose, and it is currently unknown if dosing on alternate
body weights would provide either equal immune modulation or different toxicity risks. Study results and descriptions are brief and the original reference should be reviewed before protocol use to assess other aspects of care,
speciﬁc drug product used, dose-speciﬁc parameters, nondosing related outcomes, and to ensure safe medication administration to patients.
J.Bubalo
et
al./
Biol
Blood
M
arrow
Transplant
20
(2014)
600
e
616
616
